Vol. 19 No. 1 (2013)

DOI: https://doi.org/10.5912/jcb.v19i1

Published: 2013-01-02

Commentary

The other side of innovation

Peter J. Pitts
- Requires Subscription PDF (USD 25)
Fixing a broken drug development process

John Holland
- Requires Subscription PDF (USD 25)

Article

Biotechnology valuation and governance: Drug development and board of directors composition

Chad Houston, J. Edward Graham, Peter Schuhmann
- Requires Subscription PDF (USD 25)
Chinaâ€™s heparin revisited: What went wrong and has anything changed?

Clifford S Mintz, John Liu
- Requires Subscription PDF (USD 25)
A snapshot of the successful bio-clusters around the world: Lessons for South African biotechnology

Nirvana S. Pillay, Ramazan Uctu
- Requires Subscription PDF (USD 25)
Use of medicines for carved out indications - Time for a change in approach?

Brian Cordery
- Requires Subscription PDF (USD 25)
Improving IPO market still not an exit path

G. Steven Burrill
- Requires Subscription PDF (USD 25)
NPV modelling for the selection of value-creating biosimilar development candidates

Klaus Nickisch, Kerstin M Bode-Greuel
- Requires Subscription PDF (USD 25)

Legal and Regulatory Updates

EU Legal & Regulatory Update

Ewan Grist
- Requires Subscription PDF (USD 25)